PROVETOP

Biotinylated Human SLAMF6/NTB-A Protein

Catalog No: SLAMF6-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human SLAMF6/NTB-A Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln22-Met226 (UniProt accession: Q96DU3-1).

Product Details

Molecular Aliases
ANK-T-B-antigen; NTB-A; CD352; SLAMF6; KALI; Ly108; NK-T-B-antigen; KALIb; SF2000
Protein Length
Gln22-Met226
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 26 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
SLAMF6-HB001 Bis-Tris-PAGE-white result

Biotinylated Human SLAMF6 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
SLAMF6-HB001 SEC-HPLC result

The purity of Biotinylated Human SLAMF6 is greater than 95% as determined by SEC-HPLC.

ELISA
SLAMF6-HB001 ELISA result

Immobilized Biotinylated Human SLAMF6, His-Avi tag at 0.5μg/ml (100μl/Well) on streptavidin (5μg/ml) precoated plate. Dose response curve for Anti-SLAMF6 Antibody, hFc Tag with the EC50 of 7.7ng/ml determined by ELISA (QC Test).

Background

SLAMF6 (signaling lymphocyte activation molecule 6) (Ly108 in mice, NTB-A or SF2000 in humans) is a homophilic receptor belonging to the superfamily immunoglobulin (Ig) domain-containing molecules. It is known to be widely and exclusively expressed on hematopoietic cells. The SLAMF6 intracellular portion is characterized by two ITSMs that act as binding sites for adaptor molecules such as SAP and EAT-2.

References

  1. Dragovich MA, Adam K, Strazza M, Tocheva AS, Peled M, Mor A. SLAMF6 clustering is required to augment T cell activation. PLoS One. 2019 Jun 14;14(6):e0218109. doi: 10.1371/journal.pone.0218109. PMID: 31199820; PMCID: PMC6568412.
  2. Yigit B, Wang N, Ten Hacken E, Chen SS, Bhan AK, Suarez-Fueyo A, Katsuyama E, Tsokos GC, Chiorazzi N, Wu CJ, Burger JA, Herzog RW, Engel P, Terhorst C. SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunol Res. 2019 Sep;7(9):1485-1496. doi: 10.1158/2326-6066. CIR-18-0664. Epub 2019 Jul 17. PMID: 31315913.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support